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I. Introduction 
Colorectal cancer (CRC) is a common malignancy especially in Western Europe, North 
America, Australia and New Zealand. Despite advances in surgery, chemotherapy and 
screening, it is still the second leading cause of cancer deaths in these affluent parts of the 
world (1). Prospective cohort data have linked dietary habits and lifestyle factors to CRC(2). 
Strong evidence show that immune cells, cytokines, and other immune mediators as well as 
disturbance of the host/microbiome mutualism play important roles in virtually all steps of 
colon tumourigenesis, including initiation, promotion, progression and metastasis(3,4). The 
normal colon function is fermentation of undigested food remnants such as starch and protein 
in order to extract energy from otherwise indigestible carbohydrates, production of vitamins, 
absorption of water and electrolytes and transport of waste products (faeces) to the rectum for 
excretion/defecation(5,6). Food remnants, intestinal secretions and digestive juices are 
metabolised by the bacteria (microbiome) in the colon(7). 
In the bottom of each colonic crypt, 4-6 stem cells give rise to the enormous amount of 
colonocytes and have the potential of accumulating genetic and epigenetic changes(8)[10]. As 
a result of the ongoing and rapid proliferation, the colonocytes move from the lower parts of 
the crypts up towards the colonic lumen at a speed of approximately 1 cell position per hour. 
When colonocytes reach the luminal surface they are exfoliated. Thus, a crypt is fully 
renewed in 2-8 days(8,9). This makes the colonic mucosa the organ with the highest 
proliferation rate of all organs in mammals. The rapid cell replication requires a readily 
available supply of nutrients for tissue synthesis and the process is very responsive to dietary 
changes(10). The colon hosts a major part of the human microbiome consisting of 
approximately 0.5-1 kilo of bacteria of thousands of different and mostly anaerobic strains(4), 
both diet and environment can impact on function and composition of the gut 
microbiome(11). The age related proliferation of opportunistic bacteria could contribute to an 
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environment predisposing for diseases known to increase with age, such as colorectal 
cancer(12,13). Moreover, changes in the number, diversity and stability of commensal 
bacteria (dysbiosis), especially in the Clostridia group, also can alter normal physiological 
processes and lead to diseases(4,14).  
 
Diet, lifestyle and cancer risk 
It is proven that diet plays an important role in the development of CRC, and it is equally 
accepted that the malignant transformation of colonocytes is a reaction to a constant or 
prolonged exposure to carcinogens in the colon (fig.1). Luminal events in the colon, together 
with environmental exposure and genetics interact to create adenomas and carcinomas 
(15,16). Numerous cohort studies, with  convincing evidence-based results, suppose that red 
meat and processed meat increase CRC risk, by approximately 10% for each 30 g/day 
increase of consumption. The cooking preparation of meat cause the formation of carcinogens 
such as N-nitroso compounds (NOC), heterocyclic amines and polycyclic aromatic 
hydrocarbons, and the contents of these compounds in the faecal matter are linked to 
inflammation and mucosal damage(17,18). Undigested remnants of dietary proteins and other 
nitrogenous compounds such as shed epithelial cells and nitrate/nitrite derived from processed 
meat, undergo bacterial degradation/fermentation producing ammonia, phenols and hydrogen 
sulfide. The presence of nitrogen facilitates the formation of NOC by nitrosation of 
nitrosamines and amides by bacterial decarboxylation of amino acids in the presence of a 
nitrosating agent.(19). NOC form DNA adducts (chemicals binding to the DNA), which can 
cause mutations in key oncogenes and tumour suppressor genes(20,21). Nonetheless, a high-
fat diet impacts the microbiome in a way that favors the growth of pro-inflammatory 
microorganisms, this may link high-fat diet to intestinal inflammation and other 
diseases(4,22). Possible mechanisms could be related to high intake of animal fats, that results 
in increased volume of bile acids in the colon. Bile acids undergo bacterial degradation and 
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metabolism in the colon resulting in formation of secondary bile acids such as deoxycholic 
acid and lithocholic acid, which have been shown to be carcinogenic in experimental settings 
(23).   
A high intake of dietary fibre, in particular cereal fibre and whole grains is associated with a 
reduced risk of colorectal cancer (24). Dietary fibre is the indigestible portion of food derived 
from plants and although a universally accepted definition for dietary fibre does not exist, it is 
generally agreed that the term means complex carbohydrates that are not digested in the upper 
part of the gastrointestinal tract. United States and United Kingdom health authorities 
recommend that adults consume 20-35 g of dietary fibres per day, but the average daily intake 
among the population in the Western World is only 12-18 g (15). When fibres reach the 
colon, the result is a partial or a total fermentation leading to the production of short chain 
fatty acids and gas, which affects gastrointestinal function. Short chain fatty acids reduce the 
intraluminal pH securing optimal conditions for colonocytes and decreasing the conversion of 
bile acids to secondary bile acids (14). Dietary fibres increase bulking by stimulating growth 
of normal gut flora (25), and reduce the time and concentration of carcinogens in contact with 
the bowel wall (26). The unwanted side effect of fibres is gas production, which may cause 
abdominal pain, bloating, and flatulence (27).  
The process of human aging has an impact on the gut microbiome. The aged-type gut 
microbiome is typically characterized by a reduced biodiversity, an increased abundance of 
opportunistic facultative anaerobes, and a decreased number of species with anti-
inflammatory properties (4). Aging itself involves chronic immune and inflammatory 
disturbances causing a decline in immune system functionality, thus giving rise to a chronic 
inflammatory status, called “inflamm-aging”. The age-related proliferation of opportunistic 
bacteria could both contribute to and be nurtured by inflammation, in a sort of self-sustaining 
loop, possibly creating an environment for age-related diseases, such as CRC (28). 
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Inflammation may also represent a possible molecular link between host immune response, 
intestinal microbiome and genetic events in the development of CRC. 
 
 
 
Fig. 1. Altered cellular energy metabolism in cancerogenesis. Reproduced with permission from Hagland et al. in Digestive Surgery, 2013. 
 
Cellular metabolism and cancer 
Nearly a century ago, the German physiologist and Nobel laureate Otto Warburg discovered 
an higher glucose flux through cancer cells(29). This glucose preference and metabolic switch 
observed in cancer cells is now recognized as one of the hallmarks of cancer (30). The 
increase in glycolysis is necessary to support rapid cell growth, and pathways emerging from 
the breakdown of glucose include the pentose phosphate pathway. Consequently, highly 
proliferative cells, must maintain a high carbon flux to sustain the high use of energy and 
require biomolecules to support the biosynthesis of new cells(31,32) which explains why 
common mutations in cancers genes are related to metabolism(33).  
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Pyruvate kinase proteins 
One of the glycolytic enzymes which was found to be consistently altered during 
tumourigenesis is pyruvate kinase. In 1980, Eigenbrodt supposed that pyruvate kinase M2 
(M2-PK) was phosphorylated and inactivated by various newly-discovered proteins kinase, 
including the src protein tyrosine kinase (34). Eigenbrodt also suggested that inhibition of the 
pyruvate kinase step in glycolysis is necessary for channeling metabolites into the pentose-
phosphate pathway to support nucleotide biosynthesis required by a rapidly dividing cells 
(35).  Much attention has been paid on M2-PK because  it is expressed in essentially all 
human cancers, and efforts have been made to use M2-PK as a cancer biomarker (36). 
 
Pyruvate kinase protein structure  
There are four mammalian pyruvate kinase isoforms (M1-PK,M2-PK, R-PK, L-PK) (37). 
Although a tissue may express more than one of them, individual cells generally express only 
one isoform at appreciable levels; most adult tissues express M2-PK, and expression of the 
other three isoforms is restricted to distinct tissues and cell types(38-40). The M1-PK isoform 
is found in tissues with high catabolic demand, such as muscle, heart, and  brain. L-PK is the 
major isoform in the liver and a minor isoform in the kidney, which also expresses M2-PK. R-
PK is found exclusively in red blood cells. M2-PK is the embryonic isoform and is expressed 
in many types of cancer. It is also expressed in normal proliferating cells, such as 
lymphocytes and colonocytes (39,41), but lack of proliferation does not necessarily mean lack 
of M2-PK expression.  
Mammalian pyruvate kinase is a tetrameric protein of identical subunits, which are arranged 
in a dimer-of-dimers configuration (Fig. 2,3). Each monomer contains one active site and is 
composed of three main domains – designated A, B, and C – plus a small N-terminal domain 
(42,43). The A domain is the largest domain, the active site is located in a cleft between the A 
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and B domains. The B domain is mobile and closes on the active site upon binding of the 
Mg2+-ADP substrate complex (44). The C domain is found on the opposite side of the A 
domain and contains the fructose-1,6-bisphosphate (FBP) binding pocket, present in the M2-
PK, PKL, and PKR isoforms (45,46). FBP is a major allosteric activator of M2-PK. The C 
domains form the dimer–dimer interface of the fully-associated tetramer. Thus, differences in 
amino acids located at the dimer–dimer interface are responsible for differences in FBP 
binding and allosteric regulation of the M1-PK and M2-PK isoforms (46) (fig.3).  
Pyruvate kinase is most active as a tetramer. Experiments show that M1-PK dimers retain 
catalytic activity, but that monomers are inactive (47). Unlike M1-PK, M2-PK is not a 
constitutive tetramer; the M2-PK isoform is subjected to reversible dissociation and 
inactivation when diluted in the absence of FBP ( 48). This is a key factor in tumour cells 
proliferation: when dissociated in the absence of FBP, the specific activity of M2-PK falls to 
only 4% of that found in an FBP-activated tetramer (48). Reversible activation of M2-PK 
triggered by FBP allows dynamic regulation of its enzymatic activity. 
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Fig3. Crystal structure of tetrameric M2-PK with bound ligands. The ribbon structure of tetrameric M2-PK (PDB 3BJF [8]) is shown, with a single subunit colored to represent individual 
domains. The A, B, C, and N-terminal domains are depicted in green, magenta, cyan, and yellow, respectively. Bound ligands are shown as gray spheres. In this structure, the catalytic site 
is occupied by K+, Mg2+, and oxalate (a PEP mimetic), and FBP is bound at its allosteric pocket. The binding site of amino acid binding between the A and C domains is indicated. The 
binding site for small molecule activators is also indicated.  
 
 
Biochemical aspects of M2-pyruvate kinase 
Pyruvate kinase catalyzes the direct transfer of phosphate from phosphoenolpyruvate (PEP) to 
ADP to produce ATP and pyruvate. This reaction is favourable due to the high energy 
released from PEP hydrolysis (49). During catalysis, the active site is occupied by both 
substrates (PEP and ADP, which is complexed with Mg2+) (50). A catalytic lysine residue 
stabilizes the penta-coordinate transition state that exists, as the phosphate is transferred 
directly from PEP to ADP. Tautomerization of enolpyruvate to the more stable ketoform of 
pyruvate contributes to the favourable energetics of phosphate transfer from PEP to ADP. In 
the absence of allosteric activators the M2-PK tetramers have low affinity for PEP and exhibit 
positive PEP cooperativity binding (dimeric form). Enzyme affinity for PEP at low PEP 
concentrations can be increased by binding of fructose-1,6-bisphosphate (FBP), an upstream 
glycolytic intermediate that is also thought to be the major allosteric activator of pyruvate 
kinase (51,52). Each M2-PK  subunit contains one binding site that is specific for FBP and 
distinct from the active site (Fig. 3); FBP binding increase PEP binding affinity, promote 
tetramerization, and stabilize the enzyme tetramer in the active state. Many metabolites have 
been shown to have some effect on M2-PK activity (53) most of these effects are modest and 
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require high concentrations, thus calling into question their importance for the physiological 
regulation of M2-PK. The allosteric inhibitor phenylalanine (Phe) reduces both M1-PK and 
M2-PK activity by decreasing their affinity for PEP (54-56). 
In vitro experiments have showed that M1-PK and M2-PK subunits are capable of forming 
functional heterotetramers (57). This ability may explain why most individual cells restrict 
expression to a single isoform to retain the allosteric regulatory properties of that isoform. 
However, characterization of the tissue distribution of pyruvate kinase isoforms suggest that 
pyruvate kinase heterotetramers may exist in selected situations in vivo. Adult tissues express 
more than one pyruvate kinase isoform, but heterotetramers are not observed in most cases, 
providing biochemical evidence that expression of each isoform is usually restricted to a 
particular cell type (58). 
 
M2-PK role  in cancer 
 
A proliferating cell must acquire and organize mass to replicate; this requires lipids for new 
membranes, carbohydrates for protein glycosylation, nucleotide precursors to support DNA 
replication and provide RNA for new ribosomes, amino acids and other cellular building 
blocks (59,60). ATP is critical to create and assemble these building blocks; but biosynthesis 
also need carbon and nitrogen precursors and the reducing equivalents necessary to process 
them (60,61). De novo lipid synthesis in particular requires significant expenditure of 
reducing power in the form of NADPH. Anabolic metabolism typically requires shunting of 
glucose carbon from glycolysis to biosynthetic pathways, most notably the pentose-phosphate 
pathway (PPP). The PPP produces ribose-5-phosphate and phosphoribosyl pyrophosphate 
(PRPP), which is required for nucleotide biosynthesis. The oxidative PPP also generates 
reducing equivalents in the form of NADPH. Glucose carbon is shunted from glycolysis for 
serine and glycine biosynthesis, and dihydroxyacetone phosphate is used to make glycerol-3-
phosphate that can be further processed for generation of lipids. (fig 4). M2-PK controls the 
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final step of glycolysis, and its regulation serves to integrate intracellular signalling inputs 
with the metabolic state of the cell. Down-regulation of  M2-PK activity and up-regulation of 
enzymes committing glucose to glycolysis have been thought to allow the accumulation of 
phosphorylated glycolytic intermediates, which are then available to spill into branching 
biosynthetic pathways (35). 
 
 
Fig. 4. Glycolysis with debranching synthetic processes. A large level of the highly active tetrameric form correlates with high levels of ATP and GTP, high 
ATP:ADP and GTP:GDP ratios as well as a high (ATP+GTP):(UTP+CTP) ratio. In contrast, high levels of the nearly inactive dimeric form of M2-PK correlate 
with low ATP and GTP levels, low ATP:ADP and GTP:GDP ratios as well as low (ATP+GTP):(UTP+CTP) ratio 
 
 
Interestingly, cell culture experiments suggest that the ratio of pyruvate kinase activity to (2 x) 
phosphofructokinase activity is very high in neoplastic cells (62). These data suggest that the 
regulation of pyruvate kinase activity in proliferating cells may be particularly important to 
coordinate glucose metabolism with the synthesis of deoxy-nucleotides for DNA replication. 
Regulation of M2-PK activity by tyrosine kinase signalling is crucial for metabolic changes 
that support proliferative metabolism and tumour growth in several contexts (63,64). 
Following M2-PK deletion, pyruvate kinase expression is extremely low in proliferating  
tumour cells suggesting that low pyruvate kinase activity is important to support cancer cell 
proliferation in tumours. M2-PK, but not M1-PK, was also reported to play a role in cell cycle 
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progression via β-catenin trans-activation (65) and direct phosphorylation of histone H3 (66), 
mitotic progression and chromosome segregation.  
 
Tetramer-dimer conversion of M2-PK 
When M2-PK is mainly in the inactive dimeric form and not available for glycolytic ATP 
production, energy can be provided by the degradation of the amino acid glutamine to 
glutamate, aspartate, CO2, pyruvate, citrate and lactate, a pathway termed glutaminolysis (67). 
Glutaminolysis and the truncated citric acid cycle have the metabolic advantage that a low 
amount of acetyl CoA infiltrates into the citric acid cycle, thus it is saved for fatty acid and 
cholesterol de novo synthesis. Fatty acids can be used for phospholipids synthesis or can be 
released. Fatty acids and glutamate are immunosuppressive and may be capable of protecting 
tumour cells from immune attacks (68). A key regulator of the M2-PK tetramer:dimer ratio is 
not a stationary value in tumour cells and may oscillate depending on the concentration of key 
metabolites as well as oncoproteins. A key regulator of the tetramer:dimer ratio of M2-PK and 
the metabolic budget system is the glycolytic intermediate fructose 1,6-P2 (69). 
High fructose 1,6-P2 levels induce the re-association of the inactive dimeric form of M2-PK 
to the highly active tetrameric form. Consequently, glucose is converted to pyruvate and 
lactate with the production of energy until fructose 1,6-P2 levels drop below a critical value 
that allow the dissociation to the dimeric form. 
 
Quantification of tumour M2PK 
 
M2-PK is expressed in a variety of human cancers, so much attention has been paid to this 
enzyme and many efforts have been made to use it as a cancer biomarker (36). Tumour M2-
PK (t-M2PK) , the inactive dimeric form is in fact a characteristic metabolic tumour marker 
(70, 71,72). Initial studies in patients with lung, pancreas, liver, kidney and breast cancers 
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showed increased activity of M2PK in blood as well as cancer tissues and its role is emerging 
in the management of GI cancers (73-78). It can be measured in both blood and faeces.  
 
M2PK in blood samples 
Tumour M2-PK can be detected by a highly sensitive enzyme-linked immunosorbent assay 
(ELISA) which allows its the quantitative measurement in EDTA plasma samples. The test is 
based on two monoclonal antibodies which specifically react with t-M2-PK  and do not cross-
react with other isoforms of pyruvate kinase (types L, R, and M1) (79-81). t-M2-PK 
concentrations have been shown to be affected by haemolysis of blood sample, icterus and 
lipaemia. However, a correlation with the severity of these conditions has not been reported 
(82). Tumour M2-PK levels in EDTA plasma have been found to be elevated in bacterial 
infection as opposed to severe sepsis and polytrauma (83). Other benign conditions reported 
to have t-M2-PK elevations include: rheumatic diseases (84), diabetic nephropathy (85), 
chronic cardiac failure (86), inflammatory bowel disease (87) and acute and chronic 
pancreatitis (88). The suggested mechanism  involves an increased glycolysis to meet the 
metabolic demand related to the stress of trauma and inflammatory reaction (88). Being t-M2-
PK levels measured in EDTA plasma associated with these benign conditions, theyshould be 
interpreted with caution in GI tumours. 
 
M2PK in stool samples 
Tumour M2-PK can be measured in stools by an ELISA technique composed of the same 
monoclonal antibodies used in serum/plasma assay, which specifically react with tumour M2-
PK in stool samples. In fact, CRC cells grow along the intestinal wall, when the tumor 
luminal surface is exfoliated; tumour cells can be found in stool samples, they can be used to 
measure tumour M2-PK levels. This new test does not depend on faecal blood, so it is also 
able to find non-hemorrhagic lesions. Effectively, in faecal material, the M2-PK epitope  
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remains stable more than 48 hours at room temperature and 1 year if stored at - 20 ° C. For 
this reasons, faecal determination of the M2-PK  dimeric form  was proposed in pilot studies 
forCRC diagnosis, obtaining very encouraging results (89-92). 
INFLAMMATION  
 Inflammation may also represent a possible molecular link between host immune response, 
intestinal microbiome and genetic events in the development of CRC. Increased cell 
proliferation is mediated by prostaglandins and cytokines, which again are the result of an 
accelerated arachidonic acid (AA) metabolism. The AA metabolism is one of the major 
inflammatory pathways triggered by direct contact between the bowel wall and faecal water 
irritants, pro-inflammatory microorganisms and luminal carcinogens. The most important 
enzymes converting AA into pro-inflammatory cytokines are the cyclooxygenase enzymes 
(COX) and especially the inducible isoform COX2.  
Related with the inflammation associated to the neoplastic development, is the generation of 
free radicals or reactive oxygen species (ROS). When present in excess, ROS are capable of 
damaging DNA and cellular macromolecules (93-98). In general, oxidative stress (OSS) can 
be defined as the imbalance between the generation of ROS and the availability of antioxidant 
defenses present in a system or biological compartment (99). A non-invasive method for 
direct measurement of overall OSS in humans has been developed, using a novel EPR radical-
probe. The probe, bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) decandioate di-
hydrochloride, quantitatively and instantaneously reacts with ROS (including superoxide) to 
yield the parent nitroxide, which is sufficiently persistent to be measured by EPR. This assay 
requires  an average of 100 milligrams of tissue, blood or urine (more or less a drop), that 
could be obtained during other or clinical examination(100). 
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THE ENDOCANNABINOID SIGNALLING SYSTEM 
The finding, in the early 1990s, of specific G-protein coupled receptors for the psychoactive 
component of Cannabis sativa (Δ)-D9-tetrahydrocannabinol (THC) (101), led to the discovery 
of a whole endogenous signalling system now known as the endocannabinoid system. During 
the past 15 years a remarkable amount of studies have been performed in order to understand 
the biological role of the endocannabinoid system and its regulatory functions in health and 
disease.  
The endocannabinoid system consists of the cannabinoid receptors, their ligands 
(endocannabinoids) and regulatory enzymes (i.e. for their synthesis and inactivation).  
 
Endocannabinoid receptors 
Cannabinoid receptors are part of the “metabotropic membrane receptors” super-family, they 
are characterized by seven transmembrane domains, three intracellular loops, one 
extracellular amino-terminal domain with glycosylation sites and a intracellular carboxy-
terminal domain that interacts, along with the third intracellular loop with a G-protein (fig5). 
Mammalian tissues contain at least two types of cannabinoid receptors: type 1 (CB1) and type 
2 (CB2). CB1 receptors are mostly expressed in the central nervous system but also in most 
peripheral tissues including immune cells, the reproductive system, the gastrointestinal tract 
and the lung, while CB2  receptors are most abundant in the immune system, i.e. in tonsils, 
spleen, macrophages and lymphocytes (B-cells and natural killer cells) (102). Until recently, 
the only evidence for their expression in the digestive tract was the detection of CB2 
messenger RNA in guinea-pig whole gut (103). 
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Fig5. CB1 e CB2 receptors are seven-transmembrane-domain proteins. The homology of the two receptors is about 44% (up 
to 82% in the transmembrane domains). 
 
 
 
Endocannabinoids ligands 
Endogenous ligands for the cannabinoid receptors are lipid molecules containing long-chain 
polyunsatured fatty acids, amides, esters and ethers, with different selectivity for the two 
receptor types (104,105). The most important among them are anandamide 
(arachidonylethanolamide) and 2-arachidonyl glycerol (2-AG) (fig.6). Anandamide is 
synthesized "on demand" from precursor N-Arachodonoil fosatidil-ethanolamine (NAPE) 
through the action of a specific phospholipase-D( PLD) (106). 2-AG is a product of the 
triacylglycerol metabolism and its synthesis is catalyzed by phospholipase C (PLC) (107).  
There is evidence that anandamide, and possibly also 2-AG, are removed from the 
extracellular space by a carrier mediated uptake process. Once inside the cell, anandamide is 
hydrolysed to arachidonic acid and ethanolamine by the enzyme fatty acid amide hydrolase 
(FAAH).  
 
  
Fig6. Endocannabinoid ligands: structure and mechanism. 
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Endocannabinoid metabolism – hydrolysis 
FAAH, an enzyme originally purified and cloned from rat liver microsomes (108) , catalyzes 
the hydrolysis of both AEA (as well as other long-chain fatty acid amides) and 2-AG to 
arachidonic acid and ethanolamine or glycerol, respectively. The structural and kinetic 
properties of FAAH have been widely reviewed in the literature (109) and several more or 
less selective FAAH inhibitors have also been developed (110) FAAH has an alkaline optimal 
pH and is found in microsomial membranes. Its hydrophobic domain is important for the 
formation of active oligomers, whereas its localization on intracellular membranes might be 
regulated by an SH-3 consensus, proline-rich sequence also necessary for enzymatic activity. 
The catalytic amino acid of FAAH has been identified as Ser241, and two other residues of 
the amidase consensus sequence, Ser217 and Cys249, participate in the enzymatic activity. 
(fig.7)  
 
Fig.7Endocannabinoid system metabolism 
 
 
 
Endocannabinoid system in cancer cells 
Many tumour cells acquire the ability to synthesize autocrine growth factors to which they are 
responsive, thus reducing their dependence from exogenous growth stimulation. Furthermore, 
apoptosis is a potent mechanism that limits the expansion of tumour cells by triggering their 
suicide, while defects in apoptosis underpin both carcinogenesis and metastasis (111). 
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The endocannabinoids are ubiquitously synthesized molecules, with an emerging modulating 
activity on proteins and nuclear factors that regulate cell proliferation, differentiation and 
survival. This suggests that the endocannabinoid signaling system could be involved in the 
control of fundamental cellular processes. 
CB1 receptors activation stimulates the ignition of the transduction pathway RAF-1-MEK-
ERK transduction pathway , which has the effect of 
blocking the cell cycle in phase Go/G1-S limiting the cell proliferation. This happens through 
the activation of a Gi protein that blocks the adenylate cyclase, reducing cAMP cellular levels 
and, consequently, the action of PKA. This allows the activation of transduction pathways 
(ERK, MAP-K, etc.) that promote growth control and cell differentiation. CB1 stimulation 
also causes the suppression of Ras activity, this oncogene, if expressed, increases the amount 
of  VEGF receptors. VEGF is a growth factor that induces angiogenesis. 
Cannabinoids also appear to be involved in the induction of apoptosis in tumour cells: it 
seems that the activation of the CB1 receptor causes an increase in intracellular ceramide, 
which, by increasing mitochondrial oxidative stress, induce the apoptotic mechanism. 
Apoptosis is also triggered by the activation of TRPV1 (transient receptor potential cation 
channel subfamily V member 1 or vanilloid receptor 1) by anandamide (AEA). This occurs 
through the increase of intracellular calcium, which activates the process of apoptosis. (fig 8)  
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Figure 8.  Central growth factor signaling pathways in tumor cells involved in the molecular mechanisms of cannabinoid 
action. 
 
 
 
 
Endocannbinoids and Cycloxygenase-2 (COX-2) in Cancer 
 
COX-2 enzyme  converts arachidonic acid to prostaglandins, prostacyclins and thromboxanes. 
COX-2 and prostaglandin E are commonly over-expressed in epithelial cancers including 
those found in the colon, lung, breast, and skin. In addition to metabolizing arachidonic acid, 
COX-2 catalyzes the conversion of AEA and 2-AG to  ethanolamine-conjugated and glycerol-
conjugated prostaglandins, respectively (112,113). Because these endocannabinoid-derived 
prostaglandins do not bind cannabinoid or prostaglandin receptors (114), increasing interest 
has developed in determining if these bioactive lipids mediate the cytotoxic effects of 
endocannabinoids. In colorectal carcinoma cells with elevated COX-2 expression, treatment 
with AEA resulted in increased E-series prostaglandin synthesis and cell death (115,116).  
Recently it has been shown that blockade of AEA degradation by inhibiting FAAH increased 
J-series prostaglandin synthesis and apoptosis. Thus, AEA-induced cell death in tumour cells 
which overexpress COX-2 appears to be caused by the conversion of AEA to cytotoxic 
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prostaglandins (115, 116,117,118). These responses were not reversed in the presence of 
CB1, CB2, or TRPV1 receptor antagonists. 
Selective agonists and antagonists of CB1 and CB2, inhibitors of endocannabinoid hydrolysis, 
and cannabinoid analogs have been utilized to probe the pathways involved in the effects of 
the endocannabinoid system on cancer cell apoptosis, proliferation, migration, adhesion, and 
invasion.  
 
The endocannabinoid system in colorectal cancer 
Different molecules of the endocannabinoid system have been related to the CRC and 
adenomatous polyps. In 2003 Ligresti and colleagues demonstrated that differentiation of the 
colorectal cancer cell line CaCo-2, into non-invasive cells results in increased fatty acid amide 
hydrolase (FAAH) expression, decreased in endocannabinoid levels and no responsiveness to 
cannabinoids(119). They showed that either selective CB1 receptor stimulation (as previously 
found for breast and prostate cancer cells) or activation of both CB1 and CB2 receptors causes 
inhibition of proliferation. These findings are in agreement with the presence of both CBR 
subtypes in colon normal mucosa and CRC and suggest that endocannabinoids, present in 
high amounts in CRCs and particularly, in colorectal adenomas, might function as 
endogenous inhibitors of cancer growth.  These data were also confirmed in vivo, where 
pharmacological enhancement of endocannabinoid levels (through inhibition of 
endocannabinoid hydrolysis) reduced the growth of tumour xenografts induced by the 
subcutaneous injection of rat thyroid transformed cells (120) as well as the development of 
precancerous lesions in the mouse colon (121). 
 Knowledge of the molecular factors involved in the CRC and in precancerous lesions is 
essential to identify possible markers for the identifications of these pathologies.  
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SCREENING RATES 
Colorectal cancer is one of the commonest causes of cancer death in Europe (122). CRC 
pathogenesis is a multistep process that , in most cases, goes through adenoma-carcinoma 
sequence. Many forms of CRC may be prevented by routine control, which can detect 
precancerous neoplasms and early cancers before they undergo malignant transformation or 
metastasis (123). Prevention methods have the potential to detect both cancer and polyps, 
whereas detection methods generally show a low sensitivity for polyps and an even lower 
sensitivity for cancer. However, these are easier to execute and are more cost efficient. The 
United States Preventive Task Force recommends CRC screening for the average at-risk 
population, using a faecal occult blood test (FOBT), a periodic flexible sigmoidoscopy (FS), 
or a colonoscopy (124,125). 
 
Fecal occult blood testing ( FOBT)  
Fecal occult blood testing is based on the premise that polyps and cancer bleed more than 
normal mucosa. The amount of bleeding is related to the site of the cancer (highest blood loss 
from large lesions in the cecum and ascending colon) and increases with the size of the polyp 
and the stage of the cancer, therefore it  can lead to diagnosis at an early stage.  
(i-FOBT) 
                   
Fig 9. human haemoglobin structure. 
The test is specific for human haemoglobin. It is based on antigen-antibody reaction using 
monoclonal antibodies. A latex reagent is prepared by sensitizing polystyrene latex particles 
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with rabbit IgGanti-human haemoglobin AOantibodies. If a stool sample contains 
haemoglobin, it reacts with the human anti Hb-AO antibodies that are bound to latex particles, 
thus producing a latex agglutination. This reaction is then analyzed in terms of optical density 
variation, the increase of which is directly proportional to HbAO concentration in the sample.  
Guidelines recommend the collection of two to three stool samples. Dietary restrictions and 
suspension of medication, such as aspirin, is controversial. FOBT must be done annually. 
Patients with positive results should receive a medical referral to undergo a colonoscopy 
(126). Unfortunately, colorectal screening is underused, and at least 40% of age-eligible 
adults do not adhere to up-to-date screening guidelines (127). Three strategies may improve 
colon cancer screening rates: convince the population about the importance of undergoing a 
screening test; achieve higher efficacy in standard screening tests and make them more 
available to the community (128). The current literature on Tumour M2-PK and 
endocannabinoid system molecules in CRC is limited but would justify further investigation 
of this novel cancer markers. They have a potential role in bowel cancer screening to be used 
as non-invasive screening test able to detect the pre-cancerous lesions, such as polyp 
adenoma. A proper screening trial is required in a consecutive, non selected  population, to 
compare these markers with i-FOBT test and to evaluate their efficacy, feasibility and 
influence in cancer specific diagnosis. Further investigation, therefore, are needed to define 
their clinical role. 
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II. EXPERIMENTAL PART 
METHODS 
The aim of this study  is to clarify whether FOBT,  enzyme Tumor M2-PK and 
endocannabinoid system molecules (CB1, Cb2, FAAH), could represent diagnostic non-
invasive markers, alone or in combination, for early diagnosis of CRC and its precancerous 
lesions (colorectal adenomatous polyps). 
Population.  
A prospective study was carried out in “S. Orsola-Malpighi” Hospital in Bologna in 
collaboration with “Giovanni XXIII” Hospital in Bari. It was conducted on 127 patient 
undergoing colonoscopy in Digestive Endoscopy Units. 
Eligible and not eligible criteria 
All outpatients between 50 and 75 years, both gender, asymptomatic, undergoing screening 
for bowel diseases (i.e. those exposed to risk factors and/or  with family history of crc) or 
patients  attending our Units for  abdominal symptoms related to organic bowel diseases were 
potentially eligible for the study. In particular, patients undergoing  radiological or 
endoscopic procedures for diagnosis and/or clinical management  of  bowel lesions.  Patients 
had to be able to understand the aim of the study and to answer the questionnaires. Before 
being enrolled each patient signed a consent form. Patients were excluded if they had 
undergone total colonoscopy in the previous 3 years, if they had been diagnosed with 
inflammatory bowel disease (IBD) or other gastrointestinal diseases, in case of coexisting 
serious illness or if they  were on medication associated with intestinal inflammation or 
intestinal infection (specifically sought by stool culture). In addition, patients with inadequate 
colon cleansing or subjected to incomplete colonoscopy were excluded. 
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MATERIALS 
Aim of this study was to use different techniques on different biological samples to evaluate 
markers for an early diagnosis of CRC. 
Quesionnaires 
Each patient gave us detailed individual information on dietary and lifestyle habits, family 
history and other risk factors by filling a questionnaire, helped by a trained interviewer. 
In our Unit, all endoscopies were performed without anaesthesia by the same investigator 
(DV) using an Olympus GIF 100 video endoscope. Urine,  blood, stool and  biopsy samples 
were collected the day of the endoscopy. If they had to be shipped, dry ice or refrigerated 
boxes (-20°C)  were used. 
 Biopsie samples 
Biopsy specimens were  obtained  from both healthy and pathological tissue  in  patients 
affected with CRC or  adenomatous polyps, and only in healthy tissue in “negative” patients . 
The first biopsy was  fixed in 4% paraformaldehyde,  paraffin embedded and processed for 
histo-pathological and immunohistochemical evaluations. A second biopsy was quickly 
frozen for RNA or protein extraction and the third sample (about 0.2 g) was treated with 0.5 
ml of standard saline solution containing  hydroxylamine probe  + 0.5 ml sterile distilled 
water to perform oxidative stress measurements.  
Stool samples 
The day before the endoscopy all patients collected a stool sample, that was rapidly frozen at-
20°C.  Faecal dimeric M2-PK (tumor M2-PK or t-M2-PK ) was detected  using a quantitative 
ELISA TEST composed of two monoclonal antibodies (ScheBo® • Biotech 
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AG, Giessen, Germany); cut-off: 4 U/ml. Real Time PCR to evaluate CB1, CB2 and FAAH, 
was performed using RNAs isolated from exfoliated colonocytes using "immunomagnetic 
beads". FOBT was performed with latex agglutination method, using OC autosampling bottle 
3”cuvettes (Eiken Chem, Tokio. Rivenditore Wellkang Tech, London), and analized by 
“DIANA oc sentor system”.  cut-off 100ug/ml. 
Urine and blood samples 
Peripheral blood and urine samples were collected and immediately treated with the 
hydroxylamine probe. Samples (0.5 ml) were treated with  0.5 ml of standard physiological 
solution containing the hydroxylamine probe (1mM) and deferoxamine (1mM) as a metal 
chelating agent. After 5 min incubation at 37°C, samples were  frozen in liquid nitrogen to 
stop any reaction until the EPR measurement for oxidative stress evaluation. 
ANALYSIS 
Analysis of colonoscopic findings 
The result of each colonoscopy was classified according to the lesion with the worst 
prognosis. When no adenomatous polyps or cancer were found, colonoscopy was considered 
normal and histology was named  “negative”. Adenomas were histologically classified as 
tubular, tubulovillous (25–75% villous component), villous or serrated subtypes. Advanced 
adenoma was defined as an adenoma of  at least 10 mm in diameter, with high-grade 
dysplasia, villous or tubulovillous histological characteristics, or any combination of these. 
Cancer was defined as carcinoma if invading at least the submucosa across the muscularis 
mucosa (category 5 in the revised (Vienna classification of gastrointestinal epithelial 
neoplasia). In-situ and intramucosal carcinomas were classified as high-grade dysplasia. 
Cancers were graded in 4 stages (I-IV) according to the Tumour Node Metastasis 
classification . Adenomas treated by endoscopic polypectomy and found to harbour invasive 
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cancer (transformed adenomas) were classified as stage I cancers. These cases were named  
“positive” for histology. 
Measurement of faecal tumour M2-PK and faecal occult blood test 
All faecal samples were analysed at a single central laboratory (S. Orsola Hospital, Bologna, 
Italy) whit immuno latex agglutination faecal tests (HM-Jack, Kiowa; Olympus, Tokyo, 
Japan). They were processed using an automated reading technique “OC autosampling bottle 
3” and analysed without rehydration by “ DIANA oc sentor system”, cut-off value was set at 
100 ng/ml  according to the results of a pilot trial (129). Faecal tumour M2-PK concentrations 
were determined using a commercially available sandwich ELISA based on two different 
monoclonal antibodies that  specifically recognize the dimeric form of M2-PK (ScheBo 
Biotech AG, Giessen, Germany). A positive test result was defined as more than 4.0 U/ml, as 
indicated by the manufacturer. 
Analysis of immunohistochemistry 
The expression of M2-PK and endocannabinoid system markers (CB1, CB2, FAAH)  was 
determined by a biotin free immunoenzymatic antigen detection system. This technique 
involves the sequential incubation of the colonic slides with an unconjugated rabbit or mouse 
primary antibody specific to the target antigen, an anti-rabbit or anti-mouse secondary 
antibody, a secondary antibody-HRP conjugate and substrate-chromogen (DAB ). DAB (3,3´-
diaminodbenzidine) is a sensitive colorimetric substrate used with horseradish peroxidase 
(HRP) in immunohistochemistry applications. HRP catalyzes hydrogen peroxide oxidation of 
substrates such as DAB. Electrons are transferred by HRP from the DAB to the peroxide to 
yield an insoluble brown product. 
Biopsies were formalin  fixed, paraffin embedded, sectioned at 4 µm and mounted on glass 
slides. Before proceeding with the staining protocol, the slides were 
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deparaffinised and rehydrated; a blocking step was performed whit protein block solution to 
block nonspecific background staining and peroxidative block solution to suppresses 
endogenous peroxidase activity  (EXPOSE specific HRP/DAB detection IHC, ABcam). After 
that, slides were incubated whit primary antibody overnight at 4°C.  
The primary anti-Tumor M2-PK antibody (ab38237, Abcam, 1:30) is a rabbit polyclonal anti-
human antibody directed against dimeric form of M2-PK (ScheBo Biotech UK Ltd, 
Basingstoke, UK); the primary anti- Cannabinoid receptor I (ab23703 Abcam, 1:250) and 
anti-Cannabinoid receptor II (ab3561, Abcam, dilution 1:250) are rabbit polyclonal anti-
human antibody directed respectively to Cannabinoid Receptor I and II. FAAH-1 antibody 
(ab128917, Abcam, dilution 1:250) is a mouse monoclonal anti-human antibody directed 
against fatty-acid amide hydrolase1; Anti-Ki-67 primary antibody (ab833 Abcam, dilution 
1:50) is a rabbit polyclonal anti-human antibody directed against ki-67 protein, a cellular 
marker for proliferation. The appropriate dilution for each primary antibody was determined 
by pilot experiments. Sections were visualized by adding a secondary anti-rabbit or anti-
mouse HRP conjugate antibody and chromogen substrate  (DAB).  Sections were  finally 
counterstained in hematoxylin (Sigma, St. Louis, MO, USA) to visualize nuclei. 
This trial was approved by “S.Orsola-Malpighi” Hospital Ethical Committee, according to the 
relevant institutional guidelines. Before being enrolled each patient read the information sheet 
and signed the consent format. 
Statistical analysis 
Statistical analysis for each test alone and their combination was performed by 2x2 tables, in 
comparison with the Gold Standard defined by colonoscopy-histology.  Diagnostic accuracy 
was calculated in terms of  sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV). Analysis was performed in duplicate, considering as 
“positive group” CRC alone and CRC/advanced adenoma respectively.The best accuracy was 
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obtained in the first case. This was carried out as a “blind” protocol, as the endoscopist was 
unaware of faecal tests results, and biologists were unaware of endoscopy reports.  Data 
management, statistics and  graphics (95% CIs, P<0.05) were performed using Ministat 2.1 
software. 
RESULTS 
M2-PK and FOBT investigation on selected population 
We previously analysed a population  of  280  patients selected in this way: 46% (n. 126) 
“negative”, 16.8% (n. 47) CRC, 30.4% (n.85) high risk adenoma, 7.9% (n.22) low risk 
adenoma.  
In these patients we evaluated diagnostic accuracy of M2-PK  stool test alone or  in 
combination  with i-FOBT, compared with the Gold Standard. i-FOBT and tumour M2-PK 
concentrations in these different diagnostic subgroups were determined. Histology was 
normal (apart small hyperplasic polyps) in 126 patients; CRC was found in 47 and colorectal 
adenomous polyps in 107 patients (85 were “high risk” and 22 were “low-risk” adenomas) 
(tab. 1) 
The concentrations of i-FOBT and tumour M2-PK in the different diagnostic subgroups of 
patients was determined (colon cancer/ advanced adenoma/ normal findings). For both 
markers, there were significant differences between patients with colon cancer and those with 
advanced adenoma (P<0.01) and between the groups with advanced adenoma and normal 
findings (P<0.01). Using the manufacturer’s cut-offs of 100 ng/ml faeces for i-FOBT, 4 U/ml 
for tumour M2-PK, the sensitivity, specificity PPV and NPV of the two tests for the detection 
of CRC are shown in Tables 2. i-FOBT showed the highest specificity and PPV (88.8%; 
84.1–92.3 and 52.7% ; 39.8–65.3 respectively) ; M2-PK had the best sensitivity (87.2% 
;74.8–94.0) and NPV (96.0%; 91.6–98.2). According to these results, i-FOBT+M2-PK was 
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the best combination of tests to predict  cancer  risk in our patients (Table 3). Patients who 
were found to be positive to both faecal tests had a  67%  risk of developing colon cancer. In 
contrast, in those patients who were negative to both markers, the risk of cancer was as low as 
4%. Patients with discordant test results (one positive and the other negative) had a risk of 
colon cancer of 16%, although it should be emphasized that the most common discordant 
results were the combination i-FOBT negative M2-PK positive (88 cases) rather than the 
opposite way round (only fifteen cases). So if we had tested our patients with i-FOBT test 
alone, as indicated by the screening program, 33 high risk adenoma and 14 CRC they would 
not have been detected. 
For this reason we established to investigate this markers in association with other, in 
consecutive population to define  their application in a context of CRC screening.  
 
Tab.2 Accuracy of M2-PK  and i-FOBT stool tests alone or  in combination. 
  
 Sensitivity Specificity  PPV NPV Diagnostic 
accuracy 
Likelihood 
ratio of a 
positive 
test 
Likelihood 
ratio of a 
negative 
test 
i-FOBT  61.7% (47.4–74.2) 88.8% (84.1–92.3) 52.7% (39.8–
65.3) 
92.0% (87.7–
94.9) 
84.3% (79.6–
88.1) 
5.50 (4.9–
6.2) 
0.43 (0.39–
0.48) 
M2-PK 
 cut-off 4 U/ml  
87.2% (74.8–94.0) 62.66% (56-67.7) 32.0% (24.6–
40.5) 
96.0% (91.6–
98.2) 
66.8% (61.1–
72.1) 
2.33 (2.26–
2.40) 
0.20 (0.14–
0.28) 
i-FOBT + M2-PK 
(at least one positive)  
91.5% (80.1–96.6) 57.08 (50,9-62,9) 30.1% (23.1–
38.0) 
97.1% (92.7–
98.9) 
62.9% (57.1–
68.3) 
2.13 (2.08–
2.18) 
0.14 (0.09–
0.24 
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Diet, lifestyle and cancer risk 
One hundred thirty (130) consecutive patients were considered eligible for the study at the 
two participating centres during a 12-month period. Only 3 patients were dropped because of 
inadequate colon cleansing and/or for the lack of samples,  so 127 patients were enrolled in 
this study (64 men/63 women; mean age 63, range 50–75 years).  
For each patient detailed individual information were collected by filling a questionnaire in a 
face to face interview. These included age, gender, dietary and lifestyle habits, comorbidity as 
chronic inflammatory diseases and history of medication use (aspirin, anticoagulants, 
hormones drugs) (Tab 4). The correlation of lifestyle factors and comorbidity with CRC risk 
are shown in Table 5. The prevalence of colon lesions were significantly higher in patients of 
an older age (>63 years) (91 vs. 48%; P<0.01, odd ratio 10,71) and sedentary lifestyle habits 
(64,5 vs. 17%; P<0.01, Odd Ratio 5,76) than in those without these factors. However, 
differences between gender (64 vs 49,1%, p 0,35, OD 1,81) , medication use and chronic 
inflammatory diseases, as well as red meat consumption were not statistically significant, 
maybe this is due to the number of the analyzed population. (Tab2). In contrast consumption 
of vegetable and fruit (at least three time/week)  seems to  prevent  CRC  (33% vs 5%; 
P<0,01, Odd Ratio 0,1).  
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fig. 10 Lifestyle factors correlation with CRC.  
 
The result of each colonoscopy such as macroscopic features of polyps, size (measured before 
tissue fixation), location and number of lesions, were recorded by the endoscopist. A 
dedicated pathologist confirmed lesions on all the specimens by histological examination.  
When no adenomatous polyps or cancer were found, the diagnosis was considered “negative”. 
In accordance to TNM classification,  CRC was found in 2 patients; 7 patients had high risk 
adenomas and 2 adenocarcinoma. Low-risk adenomas and hyperplasic polyps were found 
respectively in 10 and 4 patients, 7 with metaplasia, 4 had melanosis coli and only 1 had 
Crhon’s desease;  histology was definite normal in 90 patients (tab 6). We used histological 
findings as the “gold standard”. 
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Measurement of faecal tumour M2-PK and faecal occult blood test 
 
Using the manufacturer’s cut-offs of 100 ng/ml faeces for i-FOBT, 4 U/ml for tumour M2-
PK, the sensitivity, specificity PPV and NPV of the two tests for the detection of CRC are 
shown in tables 7 and 8. i-FOBT showed the highest sensitivity 80.91 % ((95% CI: 74.1–
82.3) whereas M2-PK showed performances similar to i-FOBT  in terms of specificity 
(74,14% ; (95% CI: 65.18-81.82), but markedly inferior in terms of sensitivity 63,64% (95% 
CI: 53.98 - 71.39); it showed best results to predict absence of lesions, VPN 95.56% (95% CI: 
89-98.75) Performance of combined t-M2-PK and iFOBT tests is reported in table 9.  In fact, 
patients with both positive tests have a 31.6% (95% CI: 23.10 to 39.81) risk of developing 
ccr; in contrast, in patients negative to both markers, cancer risk was as low as 2% (VPN 
98.5%, 95% CI: 93.78 -99.66). 
 
M2-PK/ 
i-FOBT  
NUMERO 
CASI  
ISTOLOGICO VPP CI (95%) VPN  (CI 95%) 
i-FOBT  19 (15%) 6+, 13- 31.6% 23.10%  to 39.81%  64.4% 55.01% to 72.32%  
M2-PK 
cut-off 4 U/ml  
39 (31%) 3+, 36- 7.7%  3.23% to 12.92%  92.3% 85.84% to 96.07%  
i-FOBT + 
M2-PK 
69 (54%)  1+, 68- 1.5%   0.05% to 4.66%  98.5%  93.78 to 99.66%  
(at least one positive)     
Tab 9 Accuracy of M2PK an i-FOBT stool test combination 
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Immunohistological staining for localisation of Tumour M2-PK 
 
To investigate t-M2-PK expression in the large bowel, first of all biopsy sections were stained 
with haematoxylin and eosin to identify the morphology and verify the origin of the tissue. 
Immunohistological staining with monoclonal antibodies which specifically recognize the 
dimeric form of M2-PK allows the visualization of the pyruvate kinase isoenzyme shift in 
tumour cells. Negative controls were uniformly negative (fig 11a). The positive tissue 
controls all showed staining. Normal large bowel showed patchy staining of crypt cells (fig 
11b). In low risk adenomas there was a signal in cytoplasm (fig 11c); high risk 
adenocarcinomas were strongly positive (++) in the cytoplasm (fig 11d). A strong signal was 
observed in carcinomas. Thus, the amount of tumour M2-PK was found to increase in patients 
with colorectal cancer cells as well as in stool samples and to correlate with pre neoplastic 
stages. 
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Fig. 11. Distribution of M2PK  immunoreactivity  in preoneoplastic and neoplastic lesions in 
colorectal cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                         
 
  
Fig.11a Negative controls Fig 11b  Normal large bowel tissue 
Fig. 11c  low risk adenomas Fig 11d  high risk adenocarcinoma 
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Immunohistological staining for localisation of CB1 and CB2 receptors 
 
To investigate the expression of cannabinoid receptors in the large bowel, the expression 
pattern of CB1 and CB2 were studied immunocytochemically in different pathological stages 
as well as in normal tissue. DAB chromogen produce a brown staining on target epitopes 
(sections are counterstained with Hematoxylin). CB1 is expressed specifically in the epithelial 
crypts. Immunostaining with the AbCam CB1-receptor antibody showed intense positive 
expression in the absorptive epithelial cells with enhanced signal in microvilli, in particular on 
the apical surface facing the lumen. (Fig.12a). The goblet cells appear negative. Sub epithelial 
plasma cells in the lamina propria are weakly positive, this  could be due to a blockage in 
antibody binding. 
In low-risk adenoma (Fig. 12b), CB1 signal intensity appears very intense, though we 
observed a change of its location in epithelial cells. In hyperplasic polyps, it is possible to 
observe nuclei irregularities, hyperplasia and absence of  CB1 receptor signal; in fact it is 
known that in advanced stages of carcinogenesis CB1 decreases until disappearing whereas it 
is still observed in the healthy tissue (Fig 12c,d ). 
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Fig. 12. Distribution of CB1 receptors immunoreactivity  in preoneoplastic and neoplastic 
lesions in colorectal cancer. 
 
  
 
 
  
 
 
Fig. 12a Normal large bowel tissue Fig. 12b  low risk adenomas 
 
Fig. 12c   high risk adenomas Fig. 12d Carcinoma  
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Similar tissue sections stained with the Abcam CB2-receptor antibody showed a different 
expression pattern. In normal colon tissue CB2 receptor is highly expressed in the 
subepithelial macrophages and plasma cells of the lamina propria, while the signal is not 
present in the epithelial crypts, nor on the apical surface of microvilli, in contrast to CB1 (fig 
13a). The presence of CB2 receptor may depend on some degree of inflammation also present 
in healthy tissues. A low epithelial CB2 immunoreactivity was observed only in some 
samples (data not shown), this is probably due to normal variations in the inflammatory status 
of the gut, which is not evident macroscopically. 
In patients with low-risk adenoma the CB2 signal is still intense, especially in areas 
surrounding the pathological tissue, where there is an ongoing inflammatory process(fig. 
13b). In low risk adenoma it  is possible to observe villi deconstruction, this is more evident 
in high risk adenoma (fig. 13c). However, CB2 signal decreases gradually and remains weak 
in the surrounding areas, where the healthy tissue presents macrophages. It is totally absent in 
carcinomatous tissue, probably due to the lack of an inflammatory response in the advanced 
stages of CRC (fig 13d). 
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Fig. 13. Distribution of CB2 receptors immunoreactivity  in preoneoplastic and neoplastic lesions in 
colorectal cancer. 
 
    
 
 
    
 
 
Immunohistological staining for localisation of FAAH1 enzyme 
 
In normal colonic tissue CB1 and CB2 receptors and FAAH enzymes are well expressed, as 
physiological regulators of the cell cycle. FAAH is the principal catabolic enzyme for a class 
of bioactive lipids called the fatty acid amides, such as anandamide.  
Fig. 13a  Normal large bowel tissue Fig. 13b  low risk adenomas 
 
Fig. 13c   high risk adenomas Fig. 13d Carcinoma  
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In normal colon tissue the endocannabinoid-system activity, is regulated by the deactivating 
enzymes, FAAH, that hydrolyzes endocannabinoid ligands (AG and 2-AG),  and indirectly 
decreases endocannabionid-system signalling (Fig14a). FAAH signal is well expressed 
already in low-risk adenoma (Fig. 14b), and increases  in advanced stages as high risk 
adenoma and carcinoma.(Fig 14c and 14d) 
An increased FAAH enzyme level in the advanced stages of CRC lower the availability of 
CB1 ligands, this reduces the inhibitory effects on cell proliferation induced by the 
endocannabinoid system. 
 
Fig. 14. Distribution of FAAH receptors immunoreactivity  in preoneoplastic and neoplastic lesions in 
colorectal cancer. 
    
 
    
Fig. 14a  Normal large bowel tissue Fig. 14b  low risk adenomas 
 
Fig. 14c   high risk adenomas Fig. 14d Carcinoma  
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The pivotal role of cell proliferation regulation has been demonstrated with Ki67 
immunostaining. Antigen KI-67 is a nuclear protein associated with cellular proliferation 
through ribosomal RNA transcription.  The fraction of Ki-67-positive tumor cells is often 
correlated with the clinical course of cancer.  
Unfortunately  so far it  was not possible to perform the following tests: Real-Time PCR  for 
CB1, CB2, FAAH enzymes in stool samples, nor expression of inflammatory molecules and 
oxidative stress in blood, biopsies and urine samples. 
DISCUSSION 
Colorectal  cancer (CRC) is one of most frequently occurring forms of cancers worldwide and 
represents a high disease burden to society and second most common cause of death from 
malignant disease in Italy. Numerous epidemiological data from around the world, show 
major geographical variation with significantly higher risk in affluent societies and 
prospective cohort data have linked dietary habits and lifestyle factors to CRC(2). Risk factors 
for developing colon cancer include age, male sex, previous sporadic colonic polyps or FAP 
(Familial adenomatous polyposis), previous CRC and environmental factors, such as diet, 
weight and general lifestyle (130). In a consecutive population that we had previously 
analyzed, the prevalence of colon lesions were significantly higher in patients with an older 
age (>63 years) (91 vs. 48%; P<0.01, odd ratio 10,71) and sedentary lifestyle habits (64,5 vs. 
17%; P<0.01, Odd Ratio 5,76) thesefinding arein accordance withthe literature (130). 
It is proven beyond reasonable doubt that diet plays an important role in the CRC 
development, and it is equally accepted that the malignant transformation of colonocytes is a 
reaction to a constant or prolonged exposure to carcinogens in the colon. Luminal events in 
the colon together with environmental exposure and genetics interact to create the conditions 
for adenomas and carcinomas development (20).  
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Meat consumption increases the risk of CRC; this is the convincing evidence-based 
conclusion from numerous  cohort studies. Numerous cohort studies and meta-analyses of 
more than 20000 cases of CRC show a 21%-28% increase in CRC risk with high intake of red 
and processed meat (15,16). However  in our population we found a not statistically 
significant correlation between red meat consumption (3 time/week o more) and risk of 
developing adenomas/CRC;  which was somewhat surprising and maybe due to the 
population size. In contrast, consumption of vegetable and fruit three time for week appears to 
lower CRC risk (33% vs 5%; P<0,01, Odd Ratio 0,1).  When fibres reaches the colon, the 
result is a partial or a total fermentation leading to the production of short chain fatty acids 
and gas, which affects gastrointestinal function. Short chain fatty acids reduce the 
intraluminal pH securing optimal conditions for colonocytes and decreasing the conversion of 
bile acids to secondary bile acids (14). Dietary fibres increase bulking by stimulating growth 
of normal gut flora, and reduce the time and concentration of carcinogens in contact with the 
bowel wall (26). 
There is an increasing interest among clinicians to understand risk factors, genetics and 
molecular biology of CRC . The precise molecular mechanism behind this phenomenon has 
yet to be defined, although some candidate pathways have been suggested.  
M2-PK 
In the bottom of each colonic crypt, 4-6 stemcells give rise to the enormous amount of 
colonocytes and host the potential of accumulating genetic and epigenetic changes (131). As a 
result of the ongoing and rapid proliferation, the colonocytes move from the lower parts of the 
crypts up towards the colonic lumen at a speed of approximately one cell position per hour. 
When colonocytes reach the luminal surface they are exfoliated (132,133).  Furthermore the 
expression of the pyruvate kinase isoenzyme type M2, which can switch between a highly 
active tetrameric form and a nearly inactive dimeric form, is an important metabolic sensor to 
adapt tumour metabolism to different metabolic conditions, such as nutrient and O2 supply. 
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Therefore, different study in vitro, with human gastric carcinoma cell lines, had demonstrated 
that tumour M2-PK reflects the metabolic activity and proliferation capacity of tumours.  
By immunohistological staining with monoclonal antibodies which specifically recognize the 
dimeric form of M2-PK, we observed its increase in patients with colonic precancerous and 
cancerous lesions. This technique shows that normal large bowel has patchy staining of crypt 
cells (fig 11b). Weakly signal appear in the colonocytes cytoplasm, in patients with low risk 
adenomas (fig 11c). Immunostaining becomes very strong in high risk adenomas, still in the 
epithelial cell cytoplasm (fig 11d). It is important to note that this increase in 
immunohistological signal correlates with tumor M2-PK  concentrations (U/ml) detected with 
quantitative ELISA test in stool samples where normal < low risk adenoma < high risk 
adenoma < CRC.This suggest that the dimeric form of M2-PK (tumour M2-PK) is released 
from gastrointestinal tumours into the stool of tumour patients, most likely by tumour necrosis 
and cell turnover, providing the possibility of diagnostic application. 
 
The quantification of the dimeric form of M2-PK in exfoliated colonocytes makes possible 
the use of t-M2-PK as a non-invasive early marker of CRC and as a tool for therapy control. 
Many cancer types may be prevented by routine controls, that allow the detection of early 
carcinogenetic phases and especially a well-timed therapeutic approach before the  malignant 
transformation and  metastases spreading. CRC screening guidelines suggest annual i-FOBT 
testing; but unfortunately, colorectal screening is underused, and at least 40% of age-eligible 
adults do not adhere to up-to-date screening guidelines. It is essential to improve standard 
screening tests  performances, to develop new and  more sensitive  diagnostic tools  making 
them available as  routine tests. For this reasons, we hypothesized that a combination of 
simple faecal tests,  performed on a single stool sample, may help to identify patients exposed 
to higher risk of  developing adenomas and/or CRC. 
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In a pivotal study  we previously  analyzed a selected population, using quantitative ELISA 
stool test (ScheBo® • Biotech AG, Giessen, Germany)  for t-M2-PK detection and i-FOBT 
test. We defined as “positive group” patients with CRC and/or advanced adenoma and as 
“negative group” patients with normal histology and low risk adenoma. We observed 
statistically significant  differences between these groups. The overall sensitivity of t-M2-PK 
test for CRC was 87% (95% CI: 75–94%); clearly  higher than  i-FOBT sensitivity, which 
was  62% (: 47–74%). t-M2-PK ELISA  specificity was  63% (95% CI: 56–69%); lower  than  
i-FOBT specificity, which was 89% (95% CI 84–92%). We found that   i-FOBT and t-M2-PK  
test combination  was the optimal ‘panel’ for  faecal tests that yielded the highest diagnostic 
accuracy for CRC; indeed, sensitivity and NVP of this combination were 91%  and  97%, 
respectively.  
Considering  the  potential role of these faecal markers in detecting adenomas, especially the 
more advanced forms, which are at a higher risk of a rapid progression to cancer,  we found  
that patients showing  positivity to both i-FOBT and t-M2-PK tests had a 79.3% (PPV) risk of 
cancer; instead patients who resulted  negative to both markers had  a risk of cancer  not 
greater than  4% (PPV). t-M2-PK marker crucial relevance is evident especially in  discordant 
test results; it is important to remark that the most common discordant results were i-FOBT 
negative /t- M2-PK positive (88 cases), the opposite situation occurs only in 15 cases.  If our 
patients had been subjected only to the i-FOBT test, as indicated by the screening program, 33 
high risk adenoma and 14 CRC would not have been diagnosed. 
Supported by these findings, we choose to continue with further investigations. In the context 
of CRC screening was important to  evaluate whether this combination of tests would give 
excellent results also in a consecutive population.  In this case stool t-M2-PK marker showed 
a lower sensitivity (74%) compared to previous results obtained in selected cases, although a 
valid VPN (95.56%) was obtained. Considering i-FOBT and M2-PK test combination, 
patients who were negative for both markers, had a cancer risk as low as 2% (NPV 98.5%). 
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However  when both markers resulted positive, the PPV for cancer risk was lower  being only  
31.6%, this is  due to the lack of a consistent number of “positive” patients. On the basis of 
these results, we  can assume that is very  important to enhance the accuracy of the tests, 
trying to increase test performances and/or by combination with other markers. 
 
Endocannabynoid system 
Components of the so-called endocannabinoid system, i.e. endocannabinoids, cannabinoid 
receptors, as well as enzymes involved in endocannabinoid synthesis, regulation and 
degradation, have been identified in the gastrointestinal tract. This molecules are implicated in 
many gastrointestinal physiological and pathophysiological processes, including epithelial 
cell growth, inflammation and motor function; futhermore, they have been related to the CRC 
and adenomatous polyps (119,120). Treatment with THC (Cannabinoid) on colorectal 
carcinoma cells, decreased cell survival signals through the CB1 receptor, mediating the 
inhibition of the RAS-MAPK / ERK and PI3K-AKT, two cell survival signals often 
deregulated in colon cancer. The mechanism is related to the activity of endocannabinoids 
ligands, that through inhibition of adenylate cyclase-CB1 dependent, reduces the activity of 
the phosphokinase A, blocking the downstream cascade, thus inhibiting EGF, which induces 
tumor cell proliferation. Based on this background, using immunohistochemistry, we  
detected CB1, CB2 and FAAH  levels in normal, adenomatous and cancerous colon mucosa. 
In healthy tissues CB1 receptors are located  in the crypts absorptive epithelial cells, with 
enhanced signal in the microvilli apical surface facing the lumen. Decrease of CB1 signals 
appear in early stages of preneoplastic lesion, such as low-risk adenoma and hyperplasic 
polyp,  where a change of  epithelial cells location was observed.  Interestingly the lack of 
CB1 receptors isrelated to colonic preneoplastic stages evolution, in CRC CB1 receptors 
decrease until disappearing, so the apoptotic effects meditated by this receptor, that ensure 
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proper cell homeostasis, are lost in carcinomas and this allows tumor cells proliferation (fig 
12). 
In contrast, the CB2 receptor, is highly expressed in normal colon tissue, in particular in 
subepithelial macrophages and plasma cells present in the lamina propria, while the signal is 
not present in the epithelial crypts, neither on the apical surface of microvilli (fig13). The 
presence of CB2 receptor may be due to a certain degree of inflammation present also in 
healthy tissues; in fact normal bowel is continuously activated immunologically by the 
presence of its normal luminal flora (134,135). For example, the presence of macrophages and 
plasma cells in the lamina propria is characteristic of normal bowel (136). In response to 
bacterial products and antigens from dietary sources, surface epithelium can produce 
cytokines and chemokines that recruit and activate mucosal immune cells (137). Interestingly, 
we had observed also that he lack of CB2 receptors is related to of colorectal cancer evolution 
stages, from low-risk adenoma to carcinoma, in accordance with Ligresti et all. Findings in 
Caco2 cells line (119). On the other hand, gut epithelium has a pivotal role in host defense 
and the increase of CB2 receptor in the first stages of neoplasia but its decrease in advanced 
stages of carcinoma, implies an additional role for this receptor in inflammation. Then we can 
assume  that  CB2  has an anti-inflammatory role in colonic epithelial cells.  
In normal colonic tissue CB1 and CB2 receptors and FAAH enzymes are well expressed, as 
physiological regulators of the cell cycle. FAAH is a member of the serine hydrolase family 
and is the principal catabolic enzyme for a class of bioactive lipids called the fatty acid 
amides (FAAs) Members of the FAAs include anandamide (N-arachidonoylethanolamine) 
and other N-acylethanolamines. 
In normal colon tissue the endocannabinoid-system activity, is regulated by deactivating 
enzymes, such as  FAAH, that hydrolyse  endocannabinoid ligands (AG and 2-AG),  and 
indirectly decrease endocannabionid-system signalling. In low-risk adenomas (Fig. 2), FAAH 
signal intensity appears well expressed and increases even more in advanced stages as high 
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risk adenoma and carcionoma. An increased FAAH enzyme level in the advanced stages of 
CRC lowers  CB1 ligands availability, this effect reduces cell proliferation inhibition 
prompted by endocannabinoids molecules (fig 14). 
CB receptors ability to reduce proliferation and induce tumour cells apoptosis, suggests a 
protective role for the endocannabinoid system  in colon cancer patients (119). 
In colorectal tumour cells, apoptotic and antiproliferative effects are mediated by CB1; 
however, CB2 receptors, indirectly, may also be involved . The hypothesized mechanism is 
based on the inhibition of tumor cells migration via CB1, and on nonapoptotic and non-
necrotic cell death in apoptosis-resistant colon cancer cells. It would be interesting to measure  
this molecules levels in exfoliated colonocytes present in stool samples, to evaluate them as 
possible non-invasive early markers in  CRC screening. 
CONCLUSIONS 
We can confirm that the endocannabinoid system play an central role in colon tumorigenesis 
control.  CB1 receptors and their ligands that regulate cell apoptosis, as well as FAAH 
inhibitors  that increase endocannabinoid system ligands, proved to have a strong protective 
role in colorectal cancer.  
It will be very interesting to measure these molecules levels also in exfoliated colonocytes 
that are present in faeces.  They, in combination with other markers (such as t-M2-PK and 
FOB), could be indicated to develop a non-invasive test for an early diagnosis  of cancerous 
and pre-cancerous colorectal lesions. 
The combination of two simple faecal tests such as i-FOBT and tumour M2-PK represents a 
highly sensitive tool for detection of precancerous lesions  and early stages of cancer (before 
malignant transformation  and  metastasis), and to classify patients into different “risk groups” 
for CRC. 
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In particular, further studies in the context of CRC screening should evaluate whether this 
combination of tests may be more sensitive  and cost-effective than FOBT alone, allowing 
Digestive Endoscopy Units to create a “priority panel” for colonoscopy management. 
Furthermore, the use of non-invasive early markers would allow patients, especially the 
elderly, to avoid an invasive endoscopy if it is not required. 
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APPENDIX 
 
M2-PK and FOBT investigation on selected population 
 
Tab.1 Histologic findings in the 280 enrolled patients 
Tab.2 Accuracy of M2-PK  and i-FOBT stool tests alone or  in combination. 
 
 
 
 
Tab. 3 Priority scheme for access to colonoscopy in symptomatic patients according to the risk of cancer as 
evaluated by the combination of two faecal tests (i-FOBT and M2-PK) 
i-FOBT+M2-PK and risk of cancer 
Number of 
patients 
Number of 
cancers 
PPV 
(%) 
CI  
(95%) 
 
 
    
Priority 1 
Both tests positive 
 
40 27 67.5 52.0–79.9 
Priority 2 
Discordant tests (+ , – and – , +) 
 
103 16 15.5 9.7–23.7 
Both tests negative 
 
135 4 2.96 1.1–7.2 
                  Total patients 278 47   
CI, confidence interval; i-FOBT, immunochemical faecal occult blood test; NPV, negative predictive value; PPV, positive predictive value. 
 
 
Endoscopic/histologic findings  Females Males Total 
Normal findings  67 (54.5) 59 (37.6) 126 (45.0) 
Advanced adenoma  28 (22.8) 57 (36.3) 85 (30.4) 
Colorectal cancer  18 (14.6) 29 (18.5) 47 (16.8) 
Low-risk adenoma  10 (8.1) 12 (7.6) 22 (7.9) 
Total  123 (100.0) 157 (100.0) 280 (100.0) 
 
 
 
 
 
 
Markers Sensitivity Specificity PPV NPV 
Diagnostic 
accuracy 
Likelihood 
ratio of a 
positive test 
Likelihood 
ratio of a 
negative test 
i-FOBT  61.7% (47.4–
74.2) 
88.8% (84.1–
92.3) 
52.7% (39.8–
65.3) 
92.0% (87.7–
94.9) 
84.3% (79.6–
88.1) 
5.50 (4.9–6.2) 0.43 (0.39–
0.48) 
M2-PK 
 cut-off 4 U/ml  
87.2% (74.8–
94.0) 
62.66% (56-
67.7) 
32.0% (24.6–
40.5) 
96.0% (91.6–
98.2) 
66.8% (61.1–
72.1) 
2.33 (2.26–2.40) 0.20 (0.14–
0.28) 
i-FOBT + M2-PK 
(at least one positive) 
91.5% (80.1–
96.6) 
57.08 (50,9-62,9) 30.1% (23.1–
38.0) 
97.1% (92.7–
98.9) 
62.9% (57.1–
68.3) 
2.13 (2.08–2.18) 0.14 (0.09–
0.24 
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Diet, lifestyle and cancer risk on consecutive population 
 
 
 
Tab 4. Answers to questionnaire in a face to face interview 
QUESTION Positive  Negative  
chronic inflammatory disease 2.4 % 97.6% 
anticoagulant drugs 7.4% 92.6% 
 
Cardioaspirin 
22.1% 77.9% 
Irritable bowel 43.4% 56.6% 
persistent constipation 41.7% 58.3% 
Hormonals drugs 10.6% 89.4% 
 
anti-inflammatory drugs 
3.3% 96.4% 
Red meat consumption 
 >4 time/week 
54% 46% 
Vegetarian 1.7% 98.3% 
Vegetable consumption 4 time/week 85.2% 14.8% 
Lifestyle 
   Sedentary 
   Medium      
   Active 
 
20.5%  
 
 
 
46.4%     
 33.1% 
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Tab 5. Lifestyle factors, comorbidities history, drugs consumption and their association with risk of CRC 
Characteristics 
Control 
(%) 
Case 
(%) 
X2 
(p-value-0,05) 
P 
 Correzione  
Yates 
OR 
Age  
   
  
 
 
>63 years 48,3 91 7,32 <0,01  5,71 10,71 
<63 years 
51,7 9 
 
 
 
 
1 
Gander  
   
 
 
 
 
Male 49,1 64 0,84 0,35  0,36 1,81 
Female  
50,9 36 
 
 
 
 
1 
Physical activity 
   
 
 
 
 
sedentary 17,2 64,5 8,59 <0,01  6,45 5,76 
Medium/active 82,8 
35,5 
 
 
 
 
1 
Red meat consumption 
   
 
 
 
 
>3days/week  51 56 0.105 0.6083  0.7455 1,21 
<3days/week 
 
48 44 
 
 
 
 
1 
Vegetable consumption  
   
  
 
 
<300 g/day  95 64 3,78 <0.001  6,32 0,1 
>300 g/day 
 
5 33 
 
 
 
 
1 
Persistent constipation  
   
  
 
1 
Yes 49,1 63,6 2,38 0.12  1,49 2,66 
No 50,9 36,4 
 
  
 
1 
 
Irritable bowel 
   
  
 
 
Yes 33 65 2,48 0.13  1,68 2,56 
No 67 35 
 
  
 
1 
anti-inflammatory drugs 
   
  
 
 
Yes 1 7 2,05 1,12  0,15 6,15 
No 99 97 
 
  
 
1 
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Fig. 10 Lifestyle factors correlation with CRC. 
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Histological diagnosis  “gold standard” 
 Tab 6. Histologial findings in the 127 enrolled patients 
Endoscopic/histologic findings N % 
CRC 2 1,5 
adenocarcinoma 2 1,5 
high risk adenomas 7 5,5 
Low-risk adenomas 10 7,8 
hyperplasic polyps 4 3,1 
metaplasia 7 5,5 
melanosis coli 4 3,1 
crhon’s desease 1 0,7 
Normal finding 90 70,8 
 
 
Faecal tumour M2-PK and faecal occult blood test 
 
Tab 7. Accuracy of M2-PK  stool test                                       Tab 8.  Accuracy of i-FOBT stool test                                           
M2-PK FECALE  IC (95%)  
sensibilità  63.64 %  53.98 % to 71.39 %  
specificità  74.14%  65.18 % to 81.82 %  
vpp  18.92 %  8.00 % to 35.16 %  
vpn  95.56 %  89.00 % to 98.75 %  
 
Tab 9 Accuracy of M2PK an i-FOBT stool test combination 
M2-PK/i-
FOBT  
NUMERO 
CASI  
ISTOLOGICO VPP  CI (95%)  VPN  CI (95%) 
i-FOBT  19 (15%) 6+, 13- 31.6% 23.10%  to 39.81%  64.4% 55.01% to 72.32%  
M2-PK 
 cut-off 4 
U/ml  
39 (31%) 3+, 36- 7.7%  3.23% to 12.92%  92.3% 85.84% to 96.07%  
i-FOBT + 
M2-PK 
(at least one 
positive)  
69 (54%)  1+, 68- 1.5%   0.05% to 4.66%  98.5%  93.78 to 99.66%  
 
i-FOBT   IC (95%)  
sensibilità  80.91 %  74.1 % to 82.3%  
specificità  74.14 %  65.18 % to 81.82 %  
vpp  25.00  %  12.71 % to 41.20 %  
vpn  98.85 %  93.74 % to 99.81 %  
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